Oruka Therapeutics, Inc. (ORKA)Healthcare | Biotechnology | Menlo Park, United States | NasdaqGM
91.15 USD
-5.40
(-5.588%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 91.13 -0.01 (-0.015%) ⇩ (Aug. 28, 2026, 7:51 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:26 a.m. EDT
The immediate outlook is driven by a sharp inflection in clinical data, with recent trial results for psoriasis triggering a surge in analyst attention and price appreciation. Despite a nine-year track record of severe capital destruction, the company currently holds a fortress-like balance sheet with substantial cash reserves and negligible debt, providing ample runway to execute its pipeline. However, the long-term investment case remains fragile; the stock has lost over 97% of its value over the past decade, and the most recent annual performance was negative, suggesting the recent rally may be a one-time catalyst rather than a sustainable trend. Options markets reflect this tension, with traders aggressively buying downside protection while maintaining modest upside exposure. For investors, this is a high-risk turnaround play where the balance sheet offers safety, but the earnings history and valuation multiples demand extreme caution. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.263083 |
| MSTL | 0.266616 |
| AutoETS | 0.266841 |
| AutoTheta | 0.267232 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.83 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.465 |
| Excess Kurtosis | 0.40 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2024-08-28 |
| Debt to Equity Ratio | 0.228 |
| Market Cap | 6,034,682,880 |
| Forward P/E | -32.17 |
| Website | https://orukatx.com |
As of Aug. 22, 2026, 2:26 a.m. EDT: Speculators are positioning for high volatility with a distinct put skew. November and December 2026 expiration data shows significantly higher implied volatility and open interest on downside strikes compared to calls, indicating hedging or insurance buying against a potential correction. While there is notable call open interest at the 110 and 120 strikes suggesting upside targets, the volume of put flow at lower strikes (40-45) outweighs the call aggression, reflecting a wait-and-see sentiment amidst the recent rally.
| Date | Dividend | Yield % |
|---|---|---|
| 2024-08-29 | 19.356 | 64.52 |
| Attribute | Value |
|---|---|
| 52 Week Change | 5.20437 |
| Address1 | 855 Oak Grove Avenue |
| Address2 | Suite 100 |
| All Time High | 75,932,640.0 |
| All Time Low | 5.49 |
| Ask | 126.45 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 859,630 |
| Average Daily Volume3 Month | 1,219,124 |
| Average Volume | 1,219,124 |
| Average Volume10Days | 859,630 |
| Bid | 71.53 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 18.202 |
| City | Menlo Park |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 91.145 |
| Current Ratio | 38.513 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 95.45 |
| Day Low | 91.01 |
| Debt To Equity | 0.228 |
| Display Name | Oruka Therapeutics |
| Dividend Date | 1,724,803,200 |
| Earnings Timestamp | 1,786,365,000 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -154,943,008 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -35.651 |
| Enterprise Value | 5,523,797,504 |
| Eps Current Year | -2.31632 |
| Eps Forward | -2.83323 |
| Eps Trailing Twelve Months | -2.04 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 93.939 |
| Fifty Day Average Change | -2.7940063 |
| Fifty Day Average Change Percent | -0.029742772 |
| Fifty Two Week Change Percent | 520.437 |
| Fifty Two Week High | 115.52 |
| Fifty Two Week High Change | -24.375 |
| Fifty Two Week High Change Percent | -0.21100242 |
| Fifty Two Week Low | 14.67 |
| Fifty Two Week Low Change | 76.475 |
| Fifty Two Week Low Change Percent | 5.21302 |
| Fifty Two Week Range | 14.67 - 115.52 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 871,047,000,000 |
| Float Shares | 56,884,063 |
| Forward Eps | -2.83323 |
| Forward P E | -32.169994 |
| Free Cashflow | -65,032,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 68 |
| Fullday Change | -5.395 |
| Fullday Change Percent | -5.58836 |
| Fullday Price | 91.13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01115 |
| Held Percent Institutions | 1.1650901 |
| Implied Shares Outstanding | 66,209,699 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://phx.corporate-ir.net/phoenix.zhtml?c=109749&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,724,889,600 |
| Last Dividend Value | 19.356 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,725,321,600 |
| Last Split Factor | 1:12 |
| Long Business Summary | Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. |
| Long Name | Oruka Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 6,034,682,880 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1877171755 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -109,688,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,393,870,632 |
| Number Of Analyst Opinions | 12 |
| Open | 95.01 |
| Operating Cashflow | -100,919,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 650 606 7910 |
| Post Market Change | -0.01499939 |
| Post Market Change Percent | -0.016456624 |
| Post Market Price | 91.13 |
| Post Market Time | 1,787,961,071 |
| Previous Close | 96.54 |
| Price Eps Current Year | -39.349052 |
| Price Hint | 2 |
| Price To Book | 5.0074167 |
| Profit Margins | 0.0 |
| Quick Ratio | 38.034 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.15385 |
| Region | US |
| Regular Market Change | -5.395 |
| Regular Market Change Percent | -5.58836 |
| Regular Market Day High | 95.45 |
| Regular Market Day Low | 91.01 |
| Regular Market Day Range | 91.01 - 95.45 |
| Regular Market Open | 95.01 |
| Regular Market Previous Close | 96.54 |
| Regular Market Price | 91.145 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 589,421 |
| Return On Assets | -0.12951 |
| Return On Equity | -0.18225999 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 66,209,699 |
| Shares Percent Shares Out | 0.1254 |
| Shares Short | 8,303,245 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 8,833,223 |
| Short Name | Oruka Therapeutics, Inc. |
| Short Percent Of Float | 0.1826 |
| Short Ratio | 9.52 |
| Source Interval | 15 |
| State | CA |
| Symbol | ORKA |
| Target High Price | 200.0 |
| Target Low Price | 102.0 |
| Target Mean Price | 153.75 |
| Target Median Price | 155.5 |
| Total Cash | 873,564,032 |
| Total Cash Per Share | 13.194 |
| Total Debt | 2,546,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 56.27085 |
| Two Hundred Day Average Change | 34.874146 |
| Two Hundred Day Average Change Percent | 0.6197551 |
| Type Disp | Equity |
| Volume | 589,421 |
| Website | https://orukatx.com |
| Zip | 94,025 |